logo

For the Inventor, By the Inventor

Kawanishi, Japan

Kaneyoshi Kato

This inventor holds 22 USPTO granted patents, primarily in Amine Compound Chemistry. Top assignees: Takeda Chemical Industries, Inc., Takeda Pharmaceutical Company Limited, Senju Pharmaceutical Co., Ltd.. Active years: 1980-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kaneyoshi Kato. Retrieved from https://idiyas.com/inventor/kaneyoshi-kato

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22

% Patents Active = 77.3

Average Co-Inventor Count = 3.3

ph-index = 12

Forward Citations = 365(Granted Patents)


Location History:

  • Osaka, JP (1990)
  • Suita, JP (1980 - 1993)
  • Hyogo, JP (1995 - 1997)
  • Kawanishi, JP (1997 - 2007)

Company Filing History:

goldMedal19 out of 1,858 
 
Takeda Chemical Industries, Inc.
 patents
silverMedal2 out of 1,226 
 
Takeda Pharmaceutical Company Limited
 patents
bronzeMedal1 out of 229 
 
Senju Pharmaceutical Co., Ltd.
 patents

Years Active: 1980-2007

Loading Chart...
Areas of Expertise:
Amine Compounds
Heterocyclic Derivatives
Quinone Production
Melanin Concentrating Hormone
Bicyclic Quinone Compounds
Aromatic Hydroxamic Acid
Cell Proliferation Inhibitor
Pharmaceutical Composition
Retinal Diseases
Ester of Ascorbic Acid
Morpholine Derivatives
Amyloid-Beta Inhibitors
22 patents (USPTO):Explore Patents
1. 7256204 - Amine compounds, their production and use (2007-08-14),
2. 7115750 - Melanin concentrating hormone antagonist (2006-10-03),
3. 6930104 - Heterocyclic derivatives (2005-08-16),
4. 6784314 - Process for producing amine derivatives (2004-08-31),
5. 6613805 - Amine compounds, their production and use (2003-09-02),
6. 6586475 - &bgr;-amyloid protein production/secretion inhibitors (2003-07-01),
7. 6329389 - Amine compounds, their production and use (2001-12-11),
8. 6326369 - Bicyclic quinone compounds, their production and use (2001-12-04),
9. 6310107 - Amine compounds, their production and use as amyloid-&bgr; production inhibitors (2001-10-30),
10. 5891916 - Aromatic hydroxamix acid compounds, their production and use (1999-04-06),
11. 5804601 - Aromatic hydroxamic acid compounds, their production and use (1998-09-08),
12. 5665769 - Pharmaceutical composition for preventing and treating retinal diseases (1997-09-09),
13. 5654296 - Condensed heterocyclic compounds, their production and use (1997-08-05),
14. 5633248 - Amine compounds, their production and use (1997-05-27),
15. 5607939 - Condensed heterocyclic compounds, their production and use (1997-03-04),

Title: **Kaneyoshi Kato: Innovator in Pharmaceutical Compounds**

Introduction

Kaneyoshi Kato, based in Kawanishi, Japan, is a distinguished inventor with a remarkable portfolio of 22 patents. His innovative contributions primarily focus on pharmaceutical compounds that address critical health issues, particularly in the field of neurodegenerative diseases.

Latest Patents

Kato's latest patents include novel amine compounds demonstrated to inhibit the production and secretion of amyloid-β proteins, which are implicated in neurodegenerative diseases. The patent describes a complex compound structure with various substituents that enhance its therapeutic efficacy. Additionally, he has developed a melanin-concentrating hormone antagonist, designed to target specific cyclic groups for potential medical applications. These advancements showcase Kato's commitment to advancing pharmaceutical science.

Career Highlights

Throughout his career, Kaneyoshi Kato has made significant contributions while working for esteemed organizations such as Takeda Chemical Industries, Inc. and Takeda Pharmaceutical Company Limited. His work at these institutions has been pivotal in the development of innovative treatments that improve patient outcomes.

Collaborations

Kato has collaborated with notable colleagues, including Jun Terauchi and Mitsuru Kakihana, showcasing the importance of teamwork and shared expertise in the field of research and development. These collaborations have likely contributed to the success and impact of his various patents.

Conclusion

In summary, Kaneyoshi Kato stands out as a prominent figure in the field of pharmaceutical innovations. His extensive patent portfolio and significant contributions to major pharmaceutical companies underline the critical role he plays in developing therapeutic solutions for complex medical challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…